Connect Biopharma to Participate at the Jefferies Virtual China Biotech Summit
October 19 2021 - 8:00AM
Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect
Biopharma" or the “Company”), a global clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients with chronic inflammatory diseases through the development
of therapies derived from T cell-driven research, today announced
that Dr. Zheng Wei, Co-Founder & CEO, and Dr. Selwyn Ho, Chief
Business Officer, will participate in a fireside chat at the
Jefferies Virtual Healthcare Conference on Tuesday, October 26,
2021 at 1:00 pm ET.
A webcast of this fireside chat will be
available on the Company’s Investor Relations page accessible here:
https://investors.connectbiopharm.com/. A replay will be available
on the Company’s website following the event.
About Connect Biopharma Holdings
LimitedConnect Biopharma Holdings Limited is a global
clinical-stage biopharmaceutical company dedicated to improving the
lives of patients living with chronic inflammatory diseases through
the development of therapies derived from our T cell-driven
research.
Our lead product candidate, CBP-201, is an
antibody designed to target interleukin-4 receptor alpha (IL-4Rα)
and is currently being evaluated in clinical trials for the
treatment of atopic dermatitis (AD), Asthma and chronic
rhinosinusitis with nasal polyps (CRSwNP). Our second lead product
candidate is CBP-307, a modulator of a T cell receptor known as
sphingosine 1-phosphate receptor 1 (S1P1) that is in clinical
trials for ulcerative colitis (UC) and Crohn’s disease (CD).
Furthermore, we have started the clinical development of CBP-174, a
peripherally restricted antagonist of histamine receptor 3, for the
treatment of pruritus associated with AD.
With headquarters in China, additional
operations in the United States and Australia, and clinical
development activities in those geographies as well as Europe,
Connect Biopharma is building a rich global pipeline of internally
designed, wholly owned small molecules and antibodies targeting
several aspects of T cell biology. For additional information about
Connect Biopharma, please visit our website at
www.connectbiopharm.com.
IR/PR CONTACTS: Lazar FINN Partners David
Carey (IR) T: +1-(212)
867-1768david.carey@finnpartners.com
Erich Sandoval (Media) +1-(646) 871-8482 or +1-(917)
497-2867erich.sandoval@finnpartners.com
Corporate
Contacts:info@connectpharm.com
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Apr 2023 to Apr 2024